Nov 12, 2026 · 1h 7m
Biotech’s uncertainty creates disciplined investment opportunities
The Quality Growth Playbook for Biotech | David Ferreiro
The episode shows how investors can pursue biotech upside without treating binary science, regulation, and valuation as interchangeable risks.
- 1Quality-growth biotech investing combines scientific research, management assessment, competitive advantages, and valuation discipline.
- 2Commercial-stage companies can support larger positions, while early binary investments require smaller sizing within a diversified portfolio.
- 3AI may improve drug-development efficiency, but evidence that it improves late-stage biological success remains limited.
Don't miss
David Ferrero explains why position size should change sharply across biotech’s development stages, separating commercial businesses from early binary bets.
The brief
David Ferrero of Times Square Capital describes a quality-growth framework built on fundamental research, management quality, competitive advantages, and valuation discipline.
Biotech remains mispriced because rare diseases, unpredictable biology, regulatory risk, and difficult clinical valuation resist simple market handicapping.
Mirum illustrates the preferred balance: a commercial rare-disease franchise with management, pipeline, and clinical upside beyond a purely binary bet.
Position sizing follows development risk: commercial-stage companies can carry more weight, while early-stage binary investments stay small across a broad portfolio.
AI could improve molecule design, trial enrollment, and patient selection, but the episode stresses that better efficiency is not yet proven biological success.
The discussion closes with sell discipline, patent duration, acquisition targets, and profitable medtech businesses that combine regulatory barriers with visible growth.
What was said on this episode
18 statements · 12 positive · 4 negative · 1 mixed · 1 neutral
- David Ferreiroon Management qualityPositive3:01
Leadership quality can materially determine investment success.
“leadership can be a real key determinant of a successful investment”
Listen at 3:01
- David Ferreiroon Biotech drug developmentPositive9:36
Drug-development success odds improve beyond phase two to above even odds.
“once you get past phase two, the risks get a little bit better or you start to look at something greater than 50-50”
Listen at 9:36
Mirum is expected to generate over $700 million in marketed-franchise sales this year.
“The company is going to sell about 700 plus million dollars of sales this year in their marketed franchise.”
Listen at 10:12
Mirum's PSC opportunity could address 20,000 patients starting next year.
“this could be a 20,000 patient market opportunity that could start for them next year”
Listen at 11:44
Mirum acquired an FOP opportunity worth $200 million for under $100 million including milestones.
“$200 million opportunity that they basically paid something less than $100 million after you tie in all the milestones.”
Listen at 12:35
Mirum has a strong, steadily growing commercial business.
“they have a pretty strong commercial business that's been growing pretty readily”
Listen at 12:48
- David Ferreiroon Commercial-stage biotech companiesPositive21:19
Commercial-stage biotech companies can receive larger portfolio positions.
“For a company like this, we're willing to make it a bigger position.”
Listen at 21:19
- David Ferreiroon Binary early-stage biotech positionsNeutral22:22
Binary phase-two or phase-three biotech positions are limited to 25–50 basis points.
“25 to 50 basis points of active weight is the kind of risk we're willing to take”
Listen at 22:22
- David Ferreiroon Biotech long-duration assetsNegative24:04
Biotech and other long-duration assets tend to move inversely with yields.
“there's an inverse correlation to yields”
Listen at 24:04
Mirum's pipeline appears substantially undervalued relative to its commercial business.
“we think we're getting a pretty substantial discount on the pipeline that they've built”
Listen at 26:57
- David Ferreiroon AI in drug developmentMixed28:15
AI has accelerated molecule design without yet materially improving biological outcomes.
“we've seen so far is like real efficiency on being able to design molecules faster, but not really, you know, a real impact on biology”
Listen at 28:15
- David Ferreiroon AI-generated drugsNegative29:20
AI-generated drugs have not improved phase-two-to-phase-three success rates.
“what we haven't seen is like the success rates from phase two to phase three improve with those drugs”
Listen at 29:20
- David Ferreiroon AI clinical-trial patient selectionPositive31:46
AI can substantially improve clinical-trial patient identification and selection.
“AI has been able to remarkably help in terms of identifying and selecting patients for clinical trials”
Listen at 31:46
- David Ferreiroon Downside price targetsNegative45:32
A breached downside target usually indicates the initial investment thesis is wrong.
“when the downside price targets breach there's probably something wrong with our initial thesis”
Listen at 45:32
- David Ferreiroon Biopharma acquisition targetsPositive53:08
Acquisition targets often combine clean data, unmet need, novelty, and a real market.
“clean data packages, areas of unmet medical need, novel compounds, or truly groundbreaking technology where there is actually a market”
Listen at 53:08
Revolution Medicines' pancreatic-cancer drug doubled overall survival in a clinical trial.
“they've doubled overall survival”
Listen at 56:00
- David Ferreiroon Medical-device companiesPositive1:04:15
Medical-device companies were trading at historically low valuations.
“they were at historical evaluation levels”
Listen at 1:04:15
- David Ferreiroon Public medical-device companiesNegative1:04:27
Public investors generally reject unprofitable medical-device companies without real revenues.
“Most public investors don't tolerate unprofitable or medical device companies that don't have actual revenues and real business tied to them.”
Listen at 1:04:27
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.